Summary
Aim of this study was the characterization of the circadian melatonin profile in de novo Parkinson patients (N=9, age 60.0±3.2 years, mean ± SEM) and the comparison of these profiles with those of controls and Parkinson patients treated with I-dopa/decarboxylase inhibitor (l-dopa/DCI). We collected 14 venous blood samples during a period of 24 hours and measured the serum melatonin levels by a radioimmuno assay. De novo Parkinson patients displayed the nocturnal melatonin peak (acrophase) at the same time as controls and significantly later than l-dopa/DCI treated patients (1:54±15.6 min [average clock time ± SEM in minutes] vs. 1:45±15.6 min vs. 0:13±40.8 min). The amount of secreted melatonin did not differ among the three groups. Stage and duration of Parkinson's disease did not correlate with the amount of secreted melatonin. Patients of the tremor subgroup, however, secreted more melatonin than patients presenting only with rigidity and akinesia. The phase advance in Parkinson patients treated with l-dopa/DCI is possibly due to a central nervous dopaminergic effect elicited by l-dopa administration and not inherent to Parkinson's disease per se.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anton-Tay F, Diaz JL, Fernandez-Guardiola A (1971) On the effect of melatonin upon human brain. Its possible therapeutical implications. Life Sci 10: 841–850
Arendt J (1978) Melatonin assays in body fluids. J Neural Transm 13: 265–278
Arendt J, Ho AK, Laud C, et al (1981) Differential effect of benserazide (Ro4-4602) on the concentration of indoleamines in rat pineal and hypothalamus. Br J Pharmacol 72: 157–162
Cotzias GC, Tang LC, Miller ST, Ginos JZ (1971) Melatonin and abnormal movements induced by l-dopa in mice. Science 173: 450–454
Critchley PHS, Malcolm GP, Malcolm PN, et al (1991) Fatigue and melatonin in Parkinson's disease. J Neurol Neurosurg Psychiatry 54: 91–92
Everett GM, Borcherding JW (1970) L-dopa: effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice. Science 168: 849–850
Fahn S (1974) “On-off” phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–441
Fertl E, Auff E, Doppelbauer A, Waldhauser F (1991) Circadian secretion pattern of melatonin in Parkinson's disease. J Neural Transm [P-D Sect] 3: 41–47
Moller M, Van Deurs B, Westergaard E (1978) Vascular permeability to proteins and peptides in the mouse pineal gland. Cell Tissue Res 195: 1–15
Moore DC, Paunier L, Sizonenko PC (1979) Effect of adrenergic stimulation and blockade on melatonin secretion in the human. In: Kappers JA, Pevet P (eds) The pineal gland of vertebrates including man. Elsevier, Amsterdam, pp 517–521
Neter J, Wasserman W, Kutner M (1985) Applied linear statistical methods, 2nd ed. Richard E. Irwin Inc, Homewood, Illinois
Notari RE (1980) Biopharmacokinetics and clinical pharmacokinetics. Dekker, New York
Papavasiliou PS, Cotzias GC, et al (1972) Melatonin and parkinsonism. JAMA 221: 88–89
Poewe W, Gerstenbrand F, Ransmayr G, Plörer S (1983) Premorbid personality of Parkinson patients. J Neural Transm 19: 215–224
Struppler A, Velbo-Groneberg P, Claussen M (1976) Clinic and pathophysiology of tremor. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basel, p 287
VanCauter E (1979) Method for characterization of 24-h temporal variation of blood components. Am J Physiol 237(3): E255-E264
Vaughan GM, Bell RD, Boyar RM (1981) Melatonin rhythm in parkinsonism treated with a dopamine agonist. In: Matthews CD, Seamark RF (eds) Pineal function. Elsevier, Amsterdam, pp 19–25
Waldhauser F, Waldhauser M (1988) Melatonin and aging. In: Miles A, Philbrick DRS, Thompson C (eds) Melatonin, clinical perspectives. Oxford University Press, Oxford, pp 174–189
Waldhauser F, Weissenbacher G, Zeitlhuber U, Waldhauser M, Frisch H, Wurtman RJ (1984) Fall in nocturnal serum melatonin levels during prepuberty and pubescence. Lancet i: 362–365
Wooten GF (1987) Pharmacokinetics of levodopa. In: Fahn S, Marsden G (eds) Movement disorders II. Butterworth, London, pp 231–248
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fertl, E., Auff, E., Doppelbauer, A. et al. Circadian secretion pattern of melatonin in de novo Parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Gen Sect 5, 227–234 (1993). https://doi.org/10.1007/BF02257677
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02257677